Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Hodgkin Disease 45Lymphoma 22Hematologic Diseases 17Lymphoma, Large-Cell, Anaplastic 15Lymphoma, Non-Hodgkin 11Recurrence 9Lymphoma, T-Cell 8Lymphoma, T-Cell, Cutaneous 6Lymphoma, T-Cell, Peripheral 5Mycosis Fungoides 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphomatoid Papulosis 2Enteropathy-Associated T-Cell Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Melanoma 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × Brentuximab Vedotin × Clear all
NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Seagen Inc.

Phase 2 Completed
161 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡